keyword
MENU ▼
Read by QxMD icon Read
search

Bicalutamide

keyword
https://www.readbyqxmd.com/read/27870564/risk-associated-with-high-dose-bicalutamide
#1
Charles G Drake
No abstract text is available yet for this article.
November 21, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27848066/molecular-mechanism-of-r-bicalutamide-switching-from-androgen-receptor-antagonist-to-agonist-induced-by-amino-acid-mutations-using-molecular-dynamics-simulations-and-free-energy-calculation
#2
Hongli Liu, Rui Han, Jiazhong Li, Huanxiang Liu, Lifang Zheng
R-bicalutamide, a first generation antiandrogen, was used to treat prostate cancer for decades. Although it is very effective at the beginning, resistance appears after 2-3 years of treatment. Mutation of androgen receptor (AR) is considered a main reason for drug resistance. It is reported that AR W741C, W741L, W741C_T877A, T877A, F876L, F876L_T877A and L701H mutations can convert R-bicalutamide from AR antagonist to agonist, but the switching mechanisms are not clear. In this study, molecular dynamics simulations and molecular mechanics generalized Born surface area (MM-GBSA) calculations were performed to analyze the interaction mechanisms between R-bicalutamide and wild type/mutant ARs...
November 15, 2016: Journal of Computer-aided Molecular Design
https://www.readbyqxmd.com/read/27771244/a-study-of-combination-bicalutamide-and-raloxifene-for-patients-with-castration-resistant-prostate-cancer
#3
Thai H Ho, Rafael Nunez-Nateras, Yue-Xian Hou, Alan H Bryce, Donald W Northfelt, Amylou C Dueck, Bryan Wong, Melissa L Stanton, Richard W Joseph, Erik P Castle
BACKGROUND: Prostate tissue expresses 2 estrogen receptor (ER) isoforms, ER-α and ER-β, and estrogen-based therapies have shown activity in preclinical studies. Raloxifene, a selective ER modulator, has inhibited the growth of prostate cancer xenograft models and was tested in a phase II trial of castration-resistant prostate cancer (CRPC), with some patients achieving stable disease. However, no studies have examined the safety of the combination of bicalutamide plus raloxifene for CRPC...
September 8, 2016: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/27756786/a-phase-ii-randomized-open-label-study-of-neoadjuvant-degarelix-versus-lhrh-agonist-in-prostate-cancer-patients-prior-to-radical-prostatectomy
#4
Rashid Sayyid, Andrew Evans, Karen Hersey, Ranjena Maloni, Antonio Hurtado-Coll, Girish Kulkarni, Antonio Finelli, Alexandre R Zlotta, Robert Hamilton, Martin Gleave, Neil Fleshner
PURPOSE: Degarelix, a new GnRH receptor antagonist with demonstrated efficacy as first-line treatment in the management of high-risk prostate cancer, possesses some theoretical advantages over LHRH analogues in terms of avoiding "testosterone flare" and lower FSH levels. We set out to determine if pre-operative degarelix influenced surrogates of disease control in a randomized phase II study. EXPERIMENTAL DESIGN: 39 patients were randomly assigned to one of 3 different neo-adjuvant arms: degarelix only, degarelix/bicalutmaide, or LHRH agonist/bicalutamide...
October 18, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/27749325/androgen-receptor-and-beyond-targeting-androgen-signaling-in-castration-resistant-prostate-cancer
#5
Zachery R Reichert, Maha Hussain
The development of metastatic castration-resistant prostate cancer (mCRPC) signals the terminal disease phase. The preceding hormone-dependent disease setting is effectively managed with androgen deprivation therapy. This foundation of treatment has a high rate of biochemical and clinical response and meaningful clinical benefit but is finite in duration as most cancers will progress to castration resistance. Historically, treatment for mCRPC entailed androgen receptor (AR) inhibitors (nilutamide, flutamide, bicalutamide), nonspecific steroidal biosynthesis inhibitors (ketoconazole, itraconazole), steroids (prednisone, diethylstilbesterol, dexamethasone), or palliative chemotherapy (mitoxantrone, estramustine), but none of these strategies impacted survival...
September 2016: Cancer Journal
https://www.readbyqxmd.com/read/27726308/selective-androgen-receptor-modulators-comparative-excretion-study-of-bicalutamide-in-bovine-urine-and-faeces
#6
Dante Rojas, Gaud Dervilly-Pinel, Nora Cesbron, Mylène Penot, Alexandre Sydor, Stéphanie Prévost, Bruno Le Bizec
Besides their development for therapeutic purposes, non-steroidal selective androgen receptor modulators (non-steroidal SARMs) are also known to impact growth-associated pathways as ligands of androgenic receptors (AR). They present a potential for abuse in sports and food-producing animals as an interesting alternative to anabolic androgenic steroids (AAS). These compounds are easily available and could therefore be (mis)used in livestock production as growth promoters. To prevent such practices, dedicated analytical strategies should be developed for specific and sensitive detection of these compounds in biological matrices...
October 11, 2016: Drug Testing and Analysis
https://www.readbyqxmd.com/read/27699828/high-content-screening-identifies-src-family-kinases-as-potential-regulators-of-ar-v7-expression-and-androgen-independent-cell-growth
#7
Adam T Szafran, Cliff Stephan, Michael Bolt, Maureen G Mancini, Marco Marcelli, Michael A Mancini
BACKGROUND: AR-V7 is an androgen receptor (AR) splice variant that lacks the ligand-binding domain and is isolated from prostate cancer cell lines. Increased expression of AR-V7 is associated with the transition from hormone-sensitive prostate cancer to more advanced castration-resistant prostate cancer (CRPC). Due to the loss of the ligand-binding domain, AR-V7 is not responsive to traditional AR-targeted therapies, and the mechanisms that regulate AR-V7 are still incompletely understood...
October 4, 2016: Prostate
https://www.readbyqxmd.com/read/27697998/targeting-hypoxic-prostate-tumours-using-the-novel-hypoxia-activated-prodrug-oct1002-inhibits-expression-of-genes-associated-with-malignant-progression
#8
Heather Nesbitt, Niall Maurice Byrne, Nicole Williams, Louise Ming, Jenny Worthington, Rachel J Errington, Laurence H Patterson, Paul Smith, Stephanie R McKeown, Declan J McKenna
Purpose To understand the role of hypoxia in prostate tumor progression, and to evaluate the ability of the novel unidirectional hypoxia-activated prodrug OCT1002 to enhance the anti-tumor effect of bicalutamide. Experimental Design The effect of OCT1002 on prostate cancer cells (LNCaP, 22Rv1, PC3) was measured in normoxia and hypoxia in vitro. In vivo, tumor growth and lung metastases were measured in mice treated with bicalutamide, OCT1002, or a combination. Dorsal skin fold chambers were used to image tumor vasculature in vivo...
October 3, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/27679555/elevated-levels-of-autophagy-related-marker-ulk1-and-mitochondrion-associated-autophagy-inhibitor-lrpprc-are-associated-with-biochemical-progression-and-overall-survival-after-androgen-deprivation-therapy-in-patients-with-metastatic-prostate-cancer
#9
Hong-Yi Zhang, Ya-Dong Ma, Ye Zhang, Jie Cui, Zi-Ming Wang
AIM: To evaluate the expression levels and prognostic significance of autophagy-related markers, UNC-51-like kinase1 (ULK1), Beclin1, microtubule-associated protein light chain 3 (LC3), autophagy-related gene 5 (ATG5) and mitochondrion-associated autophagy inhibitor, LRPPRC, in patients with metastatic prostate cancer (PCa) after androgen deprivation therapy (ADT). METHODS: Expressions of ULK1, Beclin1, LC3, ATG5 and LRPPRC were assessed by immunohistochemical examination in 198 patients with metastatic PCa who were receiving ADT (goserelin and bicalutamide)...
September 27, 2016: Journal of Clinical Pathology
https://www.readbyqxmd.com/read/27598125/cancer-associated-fibroblasts-modify-the-response-of-prostate-cancer-cells-to-androgen-and-anti-androgens-in-three-dimensional-spheroid-culture
#10
Theresa Eder, Anja Weber, Hannes Neuwirt, Georg Grünbacher, Christian Ploner, Helmut Klocker, Natalie Sampson, Iris E Eder
Androgen receptor (AR) targeting remains the gold standard treatment for advanced prostate cancer (PCa); however, treatment resistance remains a major clinical problem. To study the therapeutic effects of clinically used anti-androgens we characterized herein a tissue-mimetic three-dimensional (3D) in vitro model whereby PCa cells were cultured alone or with PCa-associated fibroblasts (CAFs). Notably, the ratio of PCa cells to CAFs significantly increased in time in favor of the tumor cells within the spheroids strongly mimicking PCa in vivo...
2016: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/27597237/re-enzalutamide-versus-bicalutamide-in-castration-resistant-prostate-cancer-the-strive-trial
#11
Takahiro Kimura, Shin Egawa
No abstract text is available yet for this article.
September 2, 2016: European Urology
https://www.readbyqxmd.com/read/27597064/re-enzalutamide-versus-bicalutamide-in-castration-resistant-prostate-cancer-the-strive-trial
#12
Samir S Taneja
No abstract text is available yet for this article.
September 2016: Journal of Urology
https://www.readbyqxmd.com/read/27588183/long-term-complete-response-of-antiandrogen-withdrawal-syndrome-in-a-patient-with-metastatic-prostate-cancer-a-case-report
#13
Masayuki Sano, Shinya Yamamoto, Sho Uehara, Takeshi Yuasa, Hitoshi Masuda, Iwao Fukui, Junji Yonese
Antiandrogen withdrawal syndrome (AWS) is a well-established phenomenon in prostate cancer treated with combined androgen blockade (CAB). AWS is generally defined as subjective and/or objective improvement following discontinuation of an antiandrogen. However, the duration of the AWS response is usually limited. In addition, a complete response is quite rare. We herein present the case of a patient who achieved complete response from AWS, with the duration of this response lasting for >6 years. A 72-year-old man with metastatic prostate cancer received CAB with a luteinizing hormone-releasing hormone analog and bicalutamide...
September 2016: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/27544580/the-effect-of-enzalutamide-and-bicalutamide-on-patient-reported-quality-of-life-outcomes-results-from-the-terrain-study
#14
Mark D Tyson, Alan Bryce
No abstract text is available yet for this article.
August 17, 2016: European Urology
https://www.readbyqxmd.com/read/27534799/predictors-of-poor-response-to-secondary-alternative-antiandrogen-therapy-with-flutamide-in-metastatic-castration-resistant-prostate-cancer
#15
Masato Yasui, Koichi Uemura, Shuko Yoneyama, Takashi Kawahara, Yusuke Hattori, Jun-Ichi Teranishi, Masahiro Inoue, Jun-Ichi Ohta, Yumiko Yokomizo, Masahiro Yao, Hiroji Uemura, Yasuhide Miyoshi
OBJECTIVE: In Japan, flutamide had been commonly used as second-line alternative antiandrogen hormonal therapy for metastatic castration-resistant prostate cancer that relapses after initial hormone therapy before new androgen pathway inhibitors became available. In this study, we attempted to identify predictive factors for efficacy of alternative antiandrogen as second-line hormone therapy. METHODS: We identified consecutive 65 patients with metastatic castration-resistant prostate cancer who were treated with alternative antiandrogen as second-line hormonal therapy (bicalutamide to flutamide)...
August 17, 2016: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27503005/mtor-inhibitors-in-castration-resistant-prostate-cancer-a-systematic-review
#16
Cara M Statz, Sara E Patterson, Susan M Mockus
BACKGROUND: The progression of prostate cancer to castration-resistant prostate cancer (CRPC) is often a result of somatic alterations in the PI3K/Akt/mTOR (mammalian target of rapamycin) pathway, suggesting that therapies targeting this pathway might lead to improved survival and efficacy. Here, we systematically evaluate the results of clinical trials investigating mTOR inhibition in CRPC and utilize preclinical data to predict clinical outcomes. METHODS: Trials included in the study were identified through PubMed and via review of conference abstracts cited by relevant review articles...
August 9, 2016: Targeted Oncology
https://www.readbyqxmd.com/read/27501397/inhibiting-androgen-receptor-nuclear-entry-in-castration-resistant-prostate-cancer
#17
Julie A Pollock, Suzanne E Wardell, Alexander A Parent, David B Stagg, Stephanie J Ellison, Holly M Alley, Christina A Chao, Scott A Lawrence, James P Stice, Ivan Spasojevic, Jennifer G Baker, Sung Hoon Kim, Donald P McDonnell, John A Katzenellenbogen, John D Norris
Clinical resistance to the second-generation antiandrogen enzalutamide in castration-resistant prostate cancer (CRPC), despite persistent androgen receptor (AR) activity in tumors, highlights an unmet medical need for next-generation antagonists. We have identified and characterized tetra-aryl cyclobutanes (CBs) as a new class of competitive AR antagonists that exhibit a unique mechanism of action. These CBs are structurally distinct from current antiandrogens (hydroxyflutamide, bicalutamide, and enzalutamide) and inhibit AR-mediated gene expression, cell proliferation, and tumor growth in several models of CRPC...
October 2016: Nature Chemical Biology
https://www.readbyqxmd.com/read/27499349/sulforaphane-increases-the-efficacy-of-anti-androgens-by-rapidly-decreasing-androgen-receptor-levels-in-prostate-cancer-cells
#18
Namrata Khurana, Sudha Talwar, Partha K Chandra, Pankaj Sharma, Asim B Abdel-Mageed, Debasis Mondal, Suresh C Sikka
Prostate cancer (PCa) cells utilize androgen for their growth. Hence, androgen deprivation therapy (ADT) using anti-androgens, e.g. bicalutamide (BIC) and enzalutamide (ENZ), is a mainstay of treatment. However, the outgrowth of castration resistant PCa (CRPC) cells remains a significant problem. These CRPC cells express androgen receptor (AR) and utilize the intratumoral androgen towards their continued growth and invasion. Sulforaphane (SFN), a naturally occurring isothiocyanate found in cruciferous vegetables, can decrease AR protein levels...
October 2016: International Journal of Oncology
https://www.readbyqxmd.com/read/27497762/impact-of-enzalutamide-compared-with-bicalutamide-on-quality-of-life-in-men-with-metastatic-castration-resistant-prostate-cancer-additional-analyses-from-the-terrain-randomised-clinical-trial
#19
Axel Heidenreich, Simon Chowdhury, Laurence Klotz, David Robert Siemens, Arnauld Villers, Cristina Ivanescu, Stefan Holmstrom, Benoit Baron, Fong Wang, Ping Lin, Neal D Shore
BACKGROUND: Improving health-related quality of life (HRQoL) is an important goal in metastatic castration-resistant prostate cancer (mCRPC). OBJECTIVE: To examine the impact of enzalutamide versus bicalutamide on HRQoL in mCRPC. DESIGN, SETTING, AND PARTICIPANTS: TERRAIN is a multinational, phase 2, randomised, double-blind study in asymptomatic/mildly symptomatic men with mCRPC (ClinicalTrials.gov, NCT01288911). Patients were randomised (1:1) via an interactive voice and web response system to enzalutamide 160mg/d (n=184) or bicalutamide 50mg/d (n=191), with androgen deprivation therapy...
August 3, 2016: European Urology
https://www.readbyqxmd.com/read/27493956/efficacy-of-immediate-switching-from-bicalutamide-to-flutamide-as-second-line-combined-androgen-blockade
#20
Yumiko Yokomizo, Takashi Kawahara, Yasuhide Miyoshi, Masako Otani, Shoji Yamanaka, Jun-Ichi Teranishi, Kazumi Noguchi, Masahiro Yao, Hiroji Uemura
We determined whether prostate specific antigen (PSA) would decrease with immediate antiandrogen switching from bicalutamide (BCL) to flutamide (FLT) in patients receiving combined androgen blockade for advanced prostate cancer. From 2002 to 2006, 20 patients who showed PSA failure after first-line hormonal therapy with a luteinizing hormone-release hormone (LH-RH) agonist and BCL were enrolled. All patients were immediately switched from BCL to FLT, administered with an LH-RH agonist, as second-line combined androgen blockade (CAB)...
2016: BioMed Research International
keyword
keyword
21362
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"